During 24 weeks of BDQ + BR treatment, the most frequent AEs (≥20%) regardless of cause or severity were arthralgia, acne and prolonged prothrombin time in Cohort 1 and increased blood creatinine phosphokinase, prolonged prothrombin time and hepatotoxicity in Cohort 2 (Table 5). Here, F2 is linked to acne.